Onset of symptomatic effect of mometasone furoate nasal spray in the treatment of nasal polyposis

Small, Catherine B.; Stryszak, Paul; Danzig, Melvyn R.; Damiano, Angela

doi:10.1016/j.jaci.2007.11.018

Cited by 39 publications

(40 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9 Corticosteroids are the most effective treatment to reduce NP size and improve nasal symptoms. 10,11 However, it is not clear whether increased infiltration of polyp tissues by neutrophils affects the clinical response to oral corticosteroids.…”

mentioning

confidence: 99%

Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy

Wen¹,

Liu²,

Zhang³

et al. 2012

Journal of Allergy and Clinical Immunology

265

View full text Add to dashboard Cite

mentioning

confidence: 99%

Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy

Wen¹,

Liu²,

Zhang³

et al. 2012

Journal of Allergy and Clinical Immunology

265

View full text Add to dashboard Cite

“…These were shown to be effective in reducing nasal symptoms (nasal blockage, secretion, sneezing, and rhinitis) and improving peak nasal inspiratory flow (PNIF) over study periods ranging from 3 to 16 weeks [13,14,68,69,70,71,72,73,75,76,78]. …”

Section: Resultsmentioning

confidence: 99%

“…In both studies, nasal polyp size was significantly reduced in the MFNS twice-daily dosing groups [13,77], and in 1 study, significant reduction was seen with MFNS 200 µg once daily [13]. A retrospective analysis of pooled data from these studies concluded that MFNS 200 µg twice daily provided significant relief of anterior rhinorrhea and PNIF by day 2, nasal congestion by day 3, postnasal drip by day 5, and improvement of sense of smell by day 13 [14]. …”

Section: Resultsmentioning

confidence: 99%

“…Characteristic symptoms of NP include nasal obstruction, congestion, discharge, and occasionally purulence, with more than 75% of patients experiencing impairment or loss of sense of smell [12,13,14]. Consequently, NP can have a marked, detrimental effect on quality of life (QoL), including physical and social functioning and mental health [15,16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evidence-Based Management of Nasal Polyposis by Intranasal Corticosteroids: From the Cause to the Clinic

Bachert¹

2011

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Nasal polyposis is an inflammatory disorder involving the mucosa of the nose and paranasal sinuses and affecting approximately 2–4% of the general population. Methods: A literature search of Medline and Embase was conducted to obtain an overview of the epidemiology, pathophysiology, and current treatment of nasal polyposis, focusing on evidence-based efficacy of intranasal corticosteroids (INSs) as primary and postoperative therapy. Recent research on INSs in nasal polyp treatment, along with notable historic findings, was reviewed. Results: Nasal polyps are mostly characterized by eosinophil infiltration, a complex inflammation of nasal mucosa, and possibly production of polyclonal IgE. Current treatment modalities include INSs, oral corticosteroids, and surgery; surgery is generally limited to those with an insufficient response to medical treatment. Because of their effects on eosinophil-dominated inflammation, INSs and oral corticosteroids are the primary medical treatment strategies. The very low (≤1%) systemic bioavailability of newer INSs minimizes the systemic adverse effects seen with oral corticosteroids. Conclusion:Based on randomized, controlled trials, guidelines recommend INSs as first-line therapy for nasal polyps and for care after polypectomy. Clinical data suggest INSs are effective in reducing polyp size and relieving nasal symptoms. INS treatment has also reduced nasal polyp recurrence in patients undergoing functional endoscopic sinus surgery. Treatment with these mainstay options has been found to improve quality of life, which, along with symptom improvement, is a key factor in disease treatment.

show abstract

“…Patients with nasal polyps applying mometasone intranasally experienced improvement in nasal symptoms within 2 to 5 days (eg, rhinorrhea, congestion, and postnasal drip) and improvement in smell within 13 days. 51 In a small double-blind, placebocontrolled study, 47 patients with CRSwNP were randomized to methylprednisolone, doxycycline, or placebo for 20 days and followed for 12 weeks. Both methylprednisolone and doxycycline reduced polyp sizes, symptoms, and markers of inflammation.…”

Section: Diagnosis and Therapy Of Sinusitismentioning

confidence: 99%

Advances in upper airway diseases and allergen immunotherapy

Sabin

Saltoun

Avila

2011

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Onset of symptomatic effect of mometasone furoate nasal spray in the treatment of nasal polyposis

Cited by 39 publications

References 25 publications

Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy

Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy

Evidence-Based Management of Nasal Polyposis by Intranasal Corticosteroids: From the Cause to the Clinic

Advances in upper airway diseases and allergen immunotherapy

Contact Info

Product

Resources

About